Dissecting the role of IER3IP1 in neurogenesis and brain malformation
Project Number5F30HD110088-02
Former Number1F30HD110088-01A1
Contact PI/Project LeaderAHN, LUCIE YEONGRAN
Awardee OrganizationCASE WESTERN RESERVE UNIVERSITY
Description
Abstract Text
Project Summary
Primary microcephaly is a structural birth defect characterized by a significantly smaller head
circumference than the mean of age and gender at birth. It is mainly linked to dysfunction of the neural progenitor
cell population, resulting in reduced neurons in the cerebral cortex. Most microcephaly-causing genes are
involved in mitosis and cytokinesis; however, recently, defects in secretory protein trafficking have been
implicated in causing microcephaly. One of the newly identified genes that are potentially involved in protein
trafficking is IER3IP1. Bi-allelic variants of IER3IP1 have been reported to cause a rare, pediatric,
neurodevelopmental condition called microcephaly with simplified gyration, generalized epilepsy, and permanent
neonatal diabetes syndrome (MEDS). MEDS patients present with severe congenital structural brain
abnormalities, including microcephaly, ventriculomegaly, and cerebral atrophy. Prior studies on IER3IP1 suggest
that its function is involved in ER to the Golgi trafficking in humans. I confirmed that the pathogenic variant blocks
ER to Golgi trafficking with a GFP trafficking reporter, and the correction of IER3IP1 mutation through
CRISPR/Cas9 restored the trafficking efficiency. Herein, I propose to focus on elucidating the function of IER3IP1
in neurogenesis and human brain development to understand how faulty protein trafficking leads to brain birth
defects.
I hypothesize that IER3IP1 regulates secretory protein trafficking during neurogenesis. I have
successfully generated and characterized cortical brain organoids and 2D neuronal culture derived from MEDS
patient-derived induced pluripotent stem cells and isogenic control cells to test this. Using these MEDS patient
cell models, I will complete the following aims: Aim 1. What is the underlying cellular mechanism of microcephaly
seen in MEDS patients with IER3IP1 p.L78P mutation? and Aim 2. Does IER3IP1 regulate the molecular
trafficking of membrane receptors important in neurodevelopment? This proposal will fill the gap in our
understanding of how protein trafficking regulates neurogenesis and provide insight into how abnormal protein
trafficking leads to structural brain abnormalities.
Public Health Relevance Statement
Project Narrative
Secretory protein trafficking enables newly synthesized proteins to be transported to the cell surface. Faulty
trafficking is implicated in developmental defects in brain development; however, how defective trafficking causes
abnormal brain development is unknown. This work aims to elucidate how inefficient protein trafficking leads to
brain birth defects and abnormal neuronal differentiation using rare disease patient-derived cell models.
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
865
DUNS Number
077758407
UEI
HJMKEF7EJW69
Project Start Date
01-April-2023
Project End Date
31-March-2025
Budget Start Date
01-April-2024
Budget End Date
31-March-2025
Project Funding Information for 2024
Total Funding
$53,974
Direct Costs
$53,974
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2024
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$53,974
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5F30HD110088-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5F30HD110088-02
Patents
No Patents information available for 5F30HD110088-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5F30HD110088-02
Clinical Studies
No Clinical Studies information available for 5F30HD110088-02
News and More
Related News Releases
No news release information available for 5F30HD110088-02
History
No Historical information available for 5F30HD110088-02
Similar Projects
No Similar Projects information available for 5F30HD110088-02